pelargonium
sidoid
medic
herb
respect
extract
use
frequent
treatment
respiratori
tract
infect
howev
effect
pelargonium
sidoid
special
extract
prepar
root
ep
human
immun
cell
fulli
understood
demonstr
ep
induc
rapid
dosedepend
product
human
blood
immun
cell
ep
cytokin
profil
proinflammatori
comparison
profil
induc
viral
bacteri
infectionmimick
agent
search
ep
target
cell
reveal
tcell
respond
ep
stimul
product
furthermor
pretreat
tcell
ep
modul
secret
subsequ
activ
contrast
lymphocyt
monocyt
show
clear
intracellular
stain
ep
treatment
accordingli
ep
predominantli
provok
activ
map
kinas
inhibit
strongli
reduc
monocyt
product
pretreat
blood
immun
cell
ep
lower
secret
caus
domin
respons
second
stimul
viral
bacteri
infectionmimick
agent
summari
demonstr
ep
activ
human
monocyt
induc
map
kinasedepend
proinflammatori
cytokin
cell
specif
modul
product
capac
mediat
known
lead
increas
acut
phase
protein
product
liver
neutrophil
gener
bone
marrow
gener
adapt
cell
today
plant
secondari
substanc
especi
polyphenol
get
focu
medic
research
south
africa
polyphenolrich
herbal
prepar
made
root
pelargonium
sidoid
pelargonium
reniform
tradit
use
treat
respiratori
gastrointestin
infect
dysmenorrhea
hepat
disord
inspir
heal
tuberculosi
charl
henri
steven
introduc
phytomed
drug
england
alreadi
seven
decad
later
special
ethanol
extract
pelargonium
sidoid
root
ep
final
develop
ep
activ
ingredi
herbal
medicin
product
umckaloabo
iso
arzneimittel
ettlingen
germani
germani
ep
approv
today
therapeut
use
patient
acut
bronchiti
addit
ep
shown
effect
clinic
trial
patient
suffer
tonsillopharyng
rhinosinus
common
cold
copd
altern
antibiot
treatment
ep
advantag
promot
microbi
resist
latter
aspect
mainli
explain
characterist
interfer
metabol
virus
bacteria
main
constitu
ep
includ
coumarin
eg
umckalin
flavanol
polyphenol
latter
compris
oligomer
proanthocyanidin
highli
abund
ep
especi
oligoand
polymer
prodelphinidin
construct
mainli
gallocatechin
epigallocatechin
compon
present
differ
interflavonoid
bond
pelargonium
sidoid
root
although
research
last
year
made
substanti
progress
respect
broad
antivir
antibacteri
efficaci
ep
exact
mode
action
ep
fulli
understood
yet
vitro
ep
show
efficaci
cellular
infect
influenza
viru
hsv
emcv
rsv
coronaviru
parainfluenza
viru
coxsacki
viru
appear
mainli
mediat
indirectli
inhibit
viru
attach
spread
differ
mode
action
underli
antibacteri
effect
ep
propos
ep
inhibit
adher
bacteria
streptococcu
pyogen
helicobact
pylori
epitheli
cell
vitro
furthermor
ciliat
cell
isol
nasal
epithelium
enhanc
ciliari
beat
frequenc
presenc
ep
allow
better
remov
excess
mucu
bacteria
regard
infect
candida
albican
ep
shown
enhanc
oxid
burst
intracellular
pathogen
kill
human
blood
phagocyt
leishmania
majorinfect
murin
macrophag
ep
increas
cellular
nitric
oxid
product
mrna
level
ino
sever
cytokin
howev
knowledg
regard
influenc
pelargonium
extract
human
immun
cell
particular
cytokin
product
still
highli
restrict
gain
insight
matter
comprehens
studi
immunoregulatori
effect
ep
human
blood
immun
cell
ep
prepar
root
pelargonium
sidoid
drug
extract
ratio
use
aqueou
ethanol
ww
extract
solvent
dri
extract
singl
batch
use
prepar
stock
solut
mgml
solut
obtain
dissolv
powder
steril
pb
contain
ethanol
follow
ultrasound
treatment
steril
filtrat
use
filter
unit
human
peripher
blood
mononuclear
cell
pbmc
isol
blood
healthi
donor
ficol
biochrom
densiti
gradient
centrifug
previous
describ
first
set
pbmc
stimul
ep
escherichia
coli
lipopolysaccharid
ligand
ngml
sigmaaldrich
polyinosinicpolycytidyl
acid
poli
c
sigmaaldrich
cytokin
mixtur
ngml
r
system
orthoclon
cilag
r
system
monoclon
antibodi
left
without
specif
treatment
ethanol
solvent
control
h
cell
cultur
supernat
recov
elisa
cytokin
product
analysi
anoth
set
pbmc
serumstarv
h
stimul
stimuli
tcr
stimul
coat
dynabead
use
cell
bead
ratio
min
cell
recov
western
blot
analysi
ep
doserespons
analys
cytokin
product
isol
pbmc
stimul
ep
concentr
rang
left
without
stimul
ethanol
control
h
concentrationrespons
analys
lipopolysaccharid
lp
ngml
poli
c
ad
first
h
incub
continu
h
studi
kinet
cytokin
product
isol
pbmc
stimul
ep
ethanol
solvent
control
intracellular
analysi
pbmc
stimul
h
ep
concentr
rang
ethanol
solvent
control
indic
ngml
phorbol
pma
ionomycin
prepar
flowcytometrybas
cytokin
analysi
studi
pbmc
pretreat
wedelolacton
sigma
aldrich
invivogen
dmso
solvent
control
sigma
aldrich
min
ep
applic
possibl
influenc
ep
pbmc
prolifer
apoptosi
test
stimul
pbmc
ethanol
solvent
control
ep
well
dmso
posit
control
apoptosi
induct
h
afterward
cell
recov
flow
cytometr
analysi
memori
tcell
purifi
isol
pbmc
neg
select
use
mac
system
memori
tcell
isol
kit
miltenyi
elisabas
cytokin
product
analysi
isol
tcell
cultur
presenc
absenc
ep
h
last
h
cultur
one
part
cell
stimul
dynabead
life
technolog
cellbead
ratio
cell
cultur
perform
use
rpmi
cultur
medium
supplement
mm
lglutamin
fetal
bovin
serum
biochrom
studi
ep
effect
collect
usag
blood
sampl
approv
clinic
institut
review
board
univers
hospit
berlin
written
inform
consent
obtain
donor
cultur
supernat
analyz
content
elisa
use
respect
detect
kit
r
system
set
quantif
carri
use
immulit
devic
respect
detect
kit
dpc
biermann
lyse
pbmc
quantif
protein
cell
lysat
sd
page
gel
electrophoresi
blot
respect
gel
carri
publish
earlier
analysi
signal
transduct
element
perform
incub
blot
antibodi
detect
phosphoakt
cell
signal
technolog
gapdh
merck
millipor
follow
incub
peroxidaseconjug
affinipur
goat
antirabbit
goat
antimous
igg
h
l
dianova
subsequ
chemiluminesc
detect
use
ecl
reagent
lumigen
analysi
intracellular
cytokin
treat
pbmc
incub
brefeldin
sigma
aldrich
last
h
treatment
afterward
cell
fix
permeabil
use
cytofixcytoperm
kit
bd
bioscienc
subsequ
stain
min
fluoresc
antibodi
detect
clone
biolegend
clone
beckmann
coulter
clone
bd
bioscienc
assess
puriti
isol
memori
thelper
cell
cell
stain
fluoresc
antibodi
detect
follow
cell
surfac
marker
describ
previous
clone
clone
clone
clone
clone
bd
bioscienc
well
clone
clone
clone
beckmann
coulter
analysi
pbmc
prolifer
total
cell
number
treatment
assess
flow
cytometri
analysi
pbmc
apoptosi
treat
cell
stain
fluoresc
annexin
v
antibodi
propidium
iodid
use
annexin
v
apoptosi
detect
kit
apc
ebiosci
accord
manufactur
instruct
afterward
proport
apoptot
cell
annexin
v
cell
evalu
data
acquisit
analys
carri
use
facscalibur
devic
cellquest
softwar
bd
bioscienc
test
signific
pairwis
differ
treatment
group
wilcoxon
matchedpair
signedrank
test
use
spss
softwar
ibm
pvalu
p
consid
indic
signific
understand
molecular
effect
ep
key
take
advantag
medic
potenti
identif
indic
far
data
regard
target
cell
effect
thereof
within
human
immun
system
lack
address
issu
first
investig
whether
ep
influenc
rest
human
immun
cell
therefor
pbmc
isol
healthi
donor
treat
control
ep
two
concentr
test
cytokin
product
comparison
cell
also
stimul
tolllik
receptor
tlr
poli
c
ligand
bacteri
lipopolysaccharid
mainli
act
antigenpres
cell
eg
monocyt
mimic
viral
bacteri
infect
respect
posit
control
mix
cytokin
abl
activ
nkcell
well
tcell
activ
antibodi
use
interestingli
cell
respond
ep
secret
level
much
higher
induc
mix
cytokin
tcr
engag
fig
furthermor
ep
slightli
trigger
product
product
clearli
smaller
induc
stimul
importantli
cytokin
profil
induc
ep
pbmc
also
differ
induc
ligand
fig
fact
ep
respons
much
proinflammatori
induc
viral
bacteri
infectionmimick
agent
fig
relev
cytotox
influenc
pbmc
prolifer
observ
ep
cytokin
increas
provok
ep
seem
due
induc
product
rate
fig
detail
investig
reveal
concentrationdepend
induct
cellular
secret
ep
clear
effect
alreadi
seen
concentr
fig
addit
kinet
analysi
ep
cytokin
product
pbmc
reveal
especi
produc
quickli
fig
afterward
level
continu
declin
probabl
result
bind
intern
cytokin
monocyt
contrast
particular
produc
slowli
ep
stimul
level
steadili
increas
time
next
studi
part
aim
identifi
cell
type
account
respons
observ
ep
blood
immun
cell
sinc
memori
helper
cell
import
cytokin
produc
first
isol
cell
human
pbmc
magnetbas
cell
sort
fig
surprisingli
relev
product
found
cell
stimul
differ
ep
concentr
fig
next
step
test
whether
ep
might
modul
cytokin
respons
activ
memori
helper
cell
howev
stimul
cell
pretreat
differ
dose
ep
result
relev
increas
secret
fig
moreov
flowcytometr
analysi
intracellular
cytokin
stain
show
popul
helper
cell
abl
produc
stimul
ep
wherea
strongli
respond
pmaionomycin
activ
fig
fig
data
suggest
within
pbmc
thcell
immun
cell
major
target
ep
action
prove
monocyt
cell
popul
sensit
among
pbmc
action
ep
analyz
intracellularli
stain
cell
ep
stimul
use
flow
cytometri
inde
observ
strong
dosedepend
induct
product
monocyt
wherebi
similar
effect
whole
pbmc
effect
alreadi
seen
fig
understand
action
ep
molecular
level
investig
signal
pathway
activ
drug
pbmc
treat
min
ep
two
differ
concentr
comparison
ligand
compris
cytokin
mixtur
antibodi
cytokin
profil
observ
pbmc
incub
ep
focus
analysi
map
kinas
pathway
respect
western
blot
analys
reveal
ep
activ
map
kinas
addit
observ
slight
activ
phosphoryl
akt
phosphoryl
pathway
wherea
expectedli
remain
unaffect
fig
line
differ
cytokin
profil
induc
ep
versu
ligand
cytokin
mixtur
antibodi
pattern
activ
kinas
ep
uniqu
pharmacolog
block
use
select
inhibitor
mek
activ
wedelolacton
kinas
observ
ep
product
monocyt
strongli
depend
activ
least
partli
depend
activ
fig
ep
frequent
use
infect
prevent
particular
autumn
winter
therefor
ask
whether
ep
pretreat
would
influenc
immun
respons
context
viral
bacteri
infect
address
question
pretreat
pbmc
increas
concentr
ep
h
follow
stimul
ligand
mimick
viral
bacteri
infect
respect
anoth
h
surprisingli
observ
ep
pretreat
concentrationdepend
inhibit
product
fig
contrast
detect
ep
concentrationdepend
high
secret
situat
fig
data
suggest
ep
pretreat
specif
modul
cytokin
product
subsequ
viral
bacteri
infect
special
extract
pelargonium
sidoid
root
ep
umckaloabo
therapeut
activ
upper
respiratori
tract
infect
current
approv
applic
acut
bronchiti
germani
surprisingli
larg
use
prepar
associ
respect
knowledg
regard
pharmacodynam
properti
fact
besid
known
antiinfect
properti
ep
direct
virus
bacteria
littl
known
molecular
effect
cellular
target
moreov
understand
pathway
via
ep
mediat
effect
cell
far
major
publish
studi
regard
effect
pelargonium
extract
concern
tissu
cell
studi
involv
immun
cell
focus
murin
macrophag
especi
studi
investig
influenc
ep
cytokin
product
human
primari
immun
cell
howev
cytokin
play
essenti
role
defens
bacteria
virus
intercellular
commun
immun
tissu
cell
therefor
focu
current
studi
unravel
possibl
influenc
ep
human
immun
cell
data
show
ep
strongli
dosedepend
induc
product
proinflammatori
cytokin
human
blood
immun
cell
moreov
less
promin
induct
antiinflammatori
act
observ
importantli
cytokin
profil
induc
ep
complet
differ
induc
viral
bacteri
infectionmimick
agent
caus
product
antiinflammatori
cytokin
milieu
observ
suggest
ep
act
immunostimul
infect
may
promot
innat
immun
defens
abil
bodi
quickli
effici
elimin
potenti
incom
microb
underli
mechan
may
includ
particular
activ
phagocyt
induct
acut
phase
protein
liver
elev
neutrophil
gener
bone
marrow
within
human
pbmc
monocyt
cell
found
target
ep
produc
high
amount
upon
treatment
result
line
previou
data
show
pelargonium
extract
act
murin
myeloid
cell
induc
product
investig
signal
cascad
induc
ep
found
strong
mapk
kinas
pathway
activ
includ
phosphoryl
jnk
furthermor
ep
slightli
provok
pathway
activ
howev
pharmacolog
blockad
result
strongli
decreas
monocyt
product
observ
signal
pattern
differ
induc
ligand
inflammatori
cytokin
engag
suggest
pelargonium
extract
affect
monocyt
via
receptor
differ
use
mention
stimuli
previous
report
major
vitro
macrophag
activ
immun
stimul
botan
caus
lipoprotein
lipopolysaccharid
deriv
bacteri
contamin
herbal
raw
materi
endophyt
colon
plant
describ
observ
ep
pathway
cytokin
pattern
differ
respons
seen
stimul
human
pbmc
bacteri
lipopolysaccharid
furthermor
analysi
ep
presenc
contamin
bacteri
lipopolysaccharid
limulu
amebocyt
lysat
lal
assay
reveal
low
content
less
eumg
equival
ngmg
current
known
constitu
ep
respons
observ
effect
cytokin
product
previou
investig
suggest
antivir
activ
extract
quantif
respect
cultur
supernat
elisa
mean
sem
cytokin
concentr
data
donor
given
percent
ep
group
control
cytokin
concentr
absenc
ep
group
pgml
pgml
pgml
respect
signific
differ
compar
ep
group
indic
p
p
wilcoxon
matchedpair
signedrank
test
primarili
due
content
prodelphinidin
complex
molecul
may
system
bioavail
studi
requir
demonstr
whether
clinic
observ
therapeut
effect
ep
mediat
compon
differ
prodelphinidin
via
stimul
immun
system
gastrointestin
tract
studi
also
demonstr
ep
preincub
immun
cell
influenc
subsequ
viral
bacteri
infectionmimick
agent
induc
cytokin
product
toward
milieu
lower
content
observ
suggest
take
ep
infect
might
reduc
flulik
symptom
infect
associ
action
furthermor
ep
caus
elev
product
infect
might
strengthen
product
acut
phase
protein
neutrophil
granulocyt
gener
bone
marrow
establish
adapt
cell
fact
differenti
cell
besid
particularli
depend
presenc
furthermor
also
cooper
induc
differenti
cell
cell
play
essenti
role
defens
microb
bodi
barrier
thu
indirect
induct
respons
ep
treatment
patient
may
promot
adapt
host
defens
differ
viral
bacteri
fungal
pathogen
respiratori
epithelia
